Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Bupivacaine liposome · 1 trial · 1 indication
AUC of NRS pain intensity scores through 48 hours. Pain intensity scores were measured on a 10-point scale (0=no pain and 10=worst possible pain)
| Arm | Type | Description |
|---|---|---|
| EXPAREL 133 mg | EXPERIMENTAL | 10 mL EXPAREL (bupivacaine liposome injectable suspension) injected into the maxilla (4 mL; 2 mL per side) and mandible (6 mL; 3 mL per side) at the end of surgery and ≥20 min after lidocaine administration |
| Placebo | PLACEBO_COMPARATOR | 10 mL normal saline injected into the maxilla (4 mL; 2 mL per side) and mandible (6 mL; 3 mL per side) at the end of surgery and ≥20 min after lidocaine administration |
| Name | Type | Description |
|---|---|---|
| Bupivacaine liposome | DRUG | Local administration |
| Placebo | DRUG | Local administration |
Inclusion Criteria: 1. Male or female, ≥18 years of age at screening. 2. Scheduled to undergo bilateral third molar extractions (i.e., extraction of all four third molars) under local anesthesia. At least one lower mandibular third molar must involve full or partial bony impaction confirmed by visu...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Align Technology, Inc. | ALGN | 2 | N/A | Undisclosed |
| Solventum Corporation | SOLV | 1 | N/A | Undisclosed |
| Haleon PLC Sponsored ADR | HLN | 1 | N/A | Undisclosed |
| DENTSPLY SIRONA, Inc. | XRAY | 1 | N/A | Undisclosed |
| Envista Holdings Corp. | NVST | 2 | - | Undisclosed |
| Smith & Nephew plc Sponsored ADR | SNN | 1 | - | Undisclosed |